Tags

Type your tag names separated by a space and hit enter

The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications.

Abstract

OBJECTIVES

To prospectively evaluate the safety of metformin administration during pregnancy in a group of PCOS patients by assessing its effect on the prevalence of gestational complications and neonatal outcome.

STUDY DESIGN

Our prospective, single centre study included 98 pregnant women with PCOS treated with metformin throughout pregnancy and 110 normal pregnant controls. All PCOS patients were hyperinsulinemic and received metformin (1700-3000 mg/day) before conception and until 37 weeks' gestation.

RESULTS

Metformin treatment in the pregnant PCOS patients resulted in significant decrease in miscarriage rate (9.1% vs 20%; p<0.05), gestational diabetes (0 vs 13%; p<0.005), and gestational hypertension (0 vs 11%; p<0.005) and a non-significant decrease in pre-eclampsia (0 vs 3%; p=.24), compared to the control group. Mean neonatal Apgar score, weight and length were comparable between the two groups.

CONCLUSIONS

Continuing metformin therapy throughout pregnancy resulted in significant reduction in pregnancy complications with concomitant improved neonatal outcome, with no serious deleterious side effects.

Authors+Show Affiliations

University of Siena, Departement of Pediatrics, Obstetric and Reproduction, S. Maria alle Scotte Hospital, Bracci Street, 53100 Siena, Italy. deleo@unisi.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

21530058

Citation

De Leo, V, et al. "The Administration of Metformin During Pregnancy Reduces Polycystic Ovary Syndrome Related Gestational Complications." European Journal of Obstetrics, Gynecology, and Reproductive Biology, vol. 157, no. 1, 2011, pp. 63-6.
De Leo V, Musacchio MC, Piomboni P, et al. The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications. Eur J Obstet Gynecol Reprod Biol. 2011;157(1):63-6.
De Leo, V., Musacchio, M. C., Piomboni, P., Di Sabatino, A., & Morgante, G. (2011). The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 157(1), pp. 63-6. doi:10.1016/j.ejogrb.2011.03.024.
De Leo V, et al. The Administration of Metformin During Pregnancy Reduces Polycystic Ovary Syndrome Related Gestational Complications. Eur J Obstet Gynecol Reprod Biol. 2011;157(1):63-6. PubMed PMID: 21530058.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications. AU - De Leo,V, AU - Musacchio,M C, AU - Piomboni,P, AU - Di Sabatino,A, AU - Morgante,G, Y1 - 2011/05/06/ PY - 2010/10/20/received PY - 2011/03/02/revised PY - 2011/03/28/accepted PY - 2011/5/3/entrez PY - 2011/5/3/pubmed PY - 2011/10/25/medline SP - 63 EP - 6 JF - European journal of obstetrics, gynecology, and reproductive biology JO - Eur. J. Obstet. Gynecol. Reprod. Biol. VL - 157 IS - 1 N2 - OBJECTIVES: To prospectively evaluate the safety of metformin administration during pregnancy in a group of PCOS patients by assessing its effect on the prevalence of gestational complications and neonatal outcome. STUDY DESIGN: Our prospective, single centre study included 98 pregnant women with PCOS treated with metformin throughout pregnancy and 110 normal pregnant controls. All PCOS patients were hyperinsulinemic and received metformin (1700-3000 mg/day) before conception and until 37 weeks' gestation. RESULTS: Metformin treatment in the pregnant PCOS patients resulted in significant decrease in miscarriage rate (9.1% vs 20%; p<0.05), gestational diabetes (0 vs 13%; p<0.005), and gestational hypertension (0 vs 11%; p<0.005) and a non-significant decrease in pre-eclampsia (0 vs 3%; p=.24), compared to the control group. Mean neonatal Apgar score, weight and length were comparable between the two groups. CONCLUSIONS: Continuing metformin therapy throughout pregnancy resulted in significant reduction in pregnancy complications with concomitant improved neonatal outcome, with no serious deleterious side effects. SN - 1872-7654 UR - https://www.unboundmedicine.com/medline/citation/21530058/The_administration_of_metformin_during_pregnancy_reduces_polycystic_ovary_syndrome_related_gestational_complications_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0301-2115(11)00182-5 DB - PRIME DP - Unbound Medicine ER -